Skip to main content

The relevance of pharmacokinetics in the development of biotechnology products

European Journal of Drug Metabolism and Pharmacokinetics volume 21, pages 93–103 (1996)Cite this article

Summary

Biotechnology derived medicines will have an increasing impact not only upon medical practice but also upon the working lives of many pharmaceutical scientists. Whilst such medicines may be viewed as highly sophisticated to the clinician and scientist, the consumer will still rightly demand that they are both efficacious and safe. Impacting as it does upon all phases of drug development and facilitating quantitative relationship between administered dose and systemic drug concentration, pharmacokinetics has an important role to play in the development ofall medicines. Bioanalysis is an essential prelude to any pharmacokinetic investigation. For many biotechnology products the immunoassay and bioassay methodologies employed are often relatively non-specific and imprecise and yield assay dependent pharmacokinetic parameters. Other factors may also confound the pharmacokinetic evaluation of biotechnological products. In vivo binding proteins (including antibodies) may not only interfere with bioanalytical methodology but also have a significant effect on the pharmacokinetics and biological activity of certain macromolecules. Antibody formation is a particular problem in the preclinical evaluation of human proteins. Unlike most conventional pharmaceuticals, the rate and time of delivery into the systemic circulation is a fundamental component of the biological activity of many biological molecules.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Biotech ’96. Pursuing Sustainability. (1995): Palo Alto, Ernst and Young LCP.

  2. Dollery C.T. (1973): Pharmacokinetics — master or servant? Eur. J. Clin. Pharmacol., 6, 1–2.

    Article  PubMed  CAS  Google Scholar 

  3. Riegelman S., Rowland M., Benet L.Z. (1973): Use of isotopes in bioavailability testing. J. Pharmacokinet. Biopharm., 1, 83–87.

    Article  CAS  Google Scholar 

  4. Ariëns E.J. (1984): Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology. Eur. J. Clin. Pharmacol., 26, 663–668.

    Article  PubMed  Google Scholar 

  5. Bailey G.S. (1984): Radioiodination of proteins. Methods Mol. Biol., 1, 325.

    PubMed  CAS  Google Scholar 

  6. Parker C.W. (1990): Radiolabelling of proteins. Methods Enzymol., 182, 721–737.

    Article  PubMed  CAS  Google Scholar 

  7. Woltanski K-P., Besch W., Keilacker H., Ziegler, M., Kohnert K-D. (1990): Radioiodination of peptide hormone and immunoglobulin preparations: comparison of the chloramine T and iodogen method. Exp. Clin. Endocrinol., 95, 39–46.

    Article  PubMed  CAS  Google Scholar 

  8. Cossum P.A., Dwyer K.A., Roth M., et al. (1992): The disposition of a human relaxin (hRIx-2) in pregnant and non-pregnant rats. Pharm. Res., 9, 415–420.

    Article  Google Scholar 

  9. Bennett H.P.J., McMartin C. (1979): Peptide hormones and their analogues: distribution, clearance, from the circulation and inactivation in vivo. Pharmacol. Rev., 30, 247–292.

    Google Scholar 

  10. Cameron D.P., Burger H.G., Catt K.J., Dong A. (1969): Metabolic clearance rate of radioiodinated human growth hormone in man. J. Clin. Invest., 48, 1600–1608.

    Article  PubMed  CAS  Google Scholar 

  11. Parker M.L., Utinger R.D., Daughaday W.H.. (1962): Studies on human growth hormone. II. The physiological disposition and metabolic fate of human growth hormone in man. J. Clin. Invest., 41, 262–268.

    Article  PubMed  CAS  Google Scholar 

  12. Regoeczi E. (1987): Iodine-labelled plasma proteins. Boca Raton, CRC, pp.6, 112, 116–117.

    Google Scholar 

  13. Schwenk W.F., Tsalikain E., Beaufrere B., Haymond M.W. (1985): Recycling of an amino acid label with prolonged isotope infusion: implications for kinetic studies. Am. J. Physiol., 248, E482-E487.

    PubMed  CAS  Google Scholar 

  14. Bloom H.G., Crocket D.J., Stewart F.S. (1958): The effects of radiation on the stability of radioiodinated human serum albumin. Br. J. Radiol., 31, 377–384.

    Article  PubMed  CAS  Google Scholar 

  15. Van der Abbeele A.D., Aronson R.A., Adelstein S.J., Kassis A.I. (1988): Does the in vitro immunoreactivity of an antibody reflect its in vivo behaviour? J. Nucl. Med. Allied Sci., 32, 260–267.

    PubMed  Google Scholar 

  16. Chan D.W., Perlstein M.T. (1987): Immunoassay — A Practical Guide. New York, Academic Press.

    Google Scholar 

  17. Kemeny D.M., Challacombe S.J. (eds) (1988): ELISA and other Solid Phase Immunoassays. New York, Wiley.

    Google Scholar 

  18. Gosling J.P. (1990): A decade of development of immunoassay methodology. Clin. Chem., 36, 1408–1427.

    PubMed  CAS  Google Scholar 

  19. Chen A.B., Baker D.L., Ferraiolo B.L.. (1991): Points to consider in correlating bioassays and immunoassays in the quantitation of peptides and proteins In: Garzone P.D., Colburn W.A., Mokotoff W.A. (Eds) Peptides, Peptoids and Proteins. Cincinnati, Harvey Whitney Books, pp. 53–71.

    Google Scholar 

  20. La Bella F.S., Geiger J.D., Glavin G.B. (1985): Administered peptides inhibit the degradation of endogenous peptides: the dilemma of distinguishing direct from indirect effects. Peptides, 6, 645–660.

    Article  Google Scholar 

  21. Pringle P.J., Hindmarsh P.C., De Silvio L., Teale J.D., Kurtz A.B., Brook C.G.D. (1989): The measurement and effect of growth hormone in the presence of growth hormone-binding antibodies. J. Endocrinol., 121, 193–199.

    Article  PubMed  CAS  Google Scholar 

  22. Lucas C., Bald L.N., Martin M.C., et al. (1989): An enzyme linked immunosorbent assay to study human relaxin in human pregnancy and in pregnant rhesus monkeys. J. Endocrinol., 120, 449–457.

    Article  PubMed  CAS  Google Scholar 

  23. Porchet H.C., Le Cotonnec J-Y., Loumaye E. (1994): Clinical pharmacology of recombinant human follicle-stimulating hormone. III. Pharmacokinetic-pharmacodynamic modelling after repeated subcutaneous administration. Fertil. Steril., 61, 687–695.

    PubMed  CAS  Google Scholar 

  24. Le Cotonnec J-Y., Porchet H.C., Beltrami V., Khan A.Z., Toon S., Rowland M. (1994): Clinical pharmacology of recombinant human follicle stimulating hormone (FSH). I. Comparative pharmacokinetics with urinary human FSH. Fertil. Steril., 61, 669–678.

    PubMed  Google Scholar 

  25. Khan A.Z., Davis J.D., Toon, S., et al. (1994): A study investigating the pharmacokinetic and pharmacodynamic equivalence of two r-hGH formulations administered subcutaneously. Br. J. Clin. Pharmacol., 38, 177P.

    Google Scholar 

  26. Toon S. (1995): Problems of assessment of bioavailability/bioequivalence of administered endogenous substances. In: Blume H.H., Midha K.K., (Eds) Bio-International 2. Bioavailability, Bioequivalence and Pharmacokinetic Studies. Stuttgart, Medpharm, pp. 161–170.

    Google Scholar 

  27. Mordenti J., Chappell W. (1989): The use of interspecies scaling in toxicokinetics. In: Yacobi A., Skelly J.P., Batra V.K. (Eds) Toxicokinetics and New Drug Development. New York, Pergamon, pp. 42–96.

    Google Scholar 

  28. Mordenti J., Green J.D. (1991): The role of pharmacokinetics and pharmacodynamics in the development of therapeutic proteins. In: Rescigno A., Thakur A.K., (Eds.) New Trends in Pharmacokinetics. New York, Plenum, pp. 411–424.

    Google Scholar 

  29. Mordenti J., Chen S., Moore J., Ferraiolo B. (1990): Total body clearance of recombinant and synthetic proteins are well described by an allometric relationship. Toxicologist, 10, 239.

    Google Scholar 

  30. Mordenti J., Shaieb D., Chow P., et al. (1991): Pre-clinical safety evaluation strategy for biomacromolecules — a perspective. In: Gad S.C. (Ee.d) Safety Assessment for Pharmaceuticals. New York, Van Nostrand Reinhold.

    Google Scholar 

  31. Working P.K. (1992): Potential effects of antibody induction by protein drugs. In: Ferraiolo B.L., Mohler M.A., Gloff C.A. (Eds). Protein Pharmacokinetics and Metabolism. New York, Plenum Press, pp. 73–92.

    Google Scholar 

  32. Vallbracht A., Trainer J., Flehmig B., Joester K.E., Niethammer D. (1981): Interferon neutralising antibodies in a patient treated with human fibroblast interferon. Nature, 289, 496–497.

    Article  PubMed  CAS  Google Scholar 

  33. Trown P.W., Kramer M.J., Dennin R.A., et al. (1983): Antibodies to human leukocyte interferon in cancer patients. Lancet, 1, 81–84.

    Article  PubMed  CAS  Google Scholar 

  34. Spiegel R.J., Spicehandler J.R., Jacobs S.L., Oden E.M. (1986): Low incidence of neutralising factors in patients receiving recombinant-alpha-2b interferon (Intron-A) Am. J. Med., 80, 223–228.

    Article  PubMed  CAS  Google Scholar 

  35. Hawkins M., Horning S., Konrand M., et al. (1985): Phase I evaluation of a synthetic mutant of β-interferon. Cancer Res., 45, 5914–5920.

    PubMed  CAS  Google Scholar 

  36. Kaplan S.L., August G.P., Blethen S.L., et al. (1986): Clinical studies with recombinant-DNA-derived methionyl human growth hormone in growth hormone deficient children. Lancet, 1, 697–700.

    Article  PubMed  CAS  Google Scholar 

  37. Fineberg S., Galloway J., Fineberg N., Rathburn M., Hufferd S. (1983): Immunogenicity of recombinant DNA human insulin. Diabetologia, 25, 465–469.

    Article  PubMed  CAS  Google Scholar 

  38. Nilsson I.M., Berntorp E., Zettervall O., Dahlback B. (1990): Noncoagulation inhibitory factor VIII antibodies after induction of tolerance to factor VIII in haemophilia A patients. Blood, 75, 378–383.

    PubMed  CAS  Google Scholar 

  39. Queseda J.R., Gutterman J.U.. (1983): Clinical study of recombinant DNA-produced leukocyte interferon (clone A) in an intermittent schedule in cancer patients. J. Natl. Cancer Inst., 70, 1041–1046.

    Google Scholar 

  40. Rosenblum M.G., Unger B.W., Gutterman J.U., Hersh E.M., David G.S., Fincke J.M. (1985): Modification of human leucocyte interferon pharmacology with monoclonal antibody. Cancer Res., 45, 2421–2424.

    PubMed  CAS  Google Scholar 

  41. Capon D.J., Charnow S.M., Mordenti J., et al. (1989): Designing CD4 immunadhesins for AIDS therapy. Nature, 337, 525–531.

    Article  PubMed  CAS  Google Scholar 

  42. Sell S. (1987): Immunology, Immunopathology and Immunity, 4th edn. Amsterdam, Elsevier.

    Google Scholar 

  43. Berson S.A., Yalow R.S. (1966): State of human growth hormone in plasma and changes in stored solutions of pituitary growth hormone. J. Biol. Chem., 241, 5745–5749.

    PubMed  CAS  Google Scholar 

  44. Baumann G., Stolar M.W., Amburn K., Barsario C.P., De Vries B.C. (1986): A specific growth hormone-binding protein in human plasma: initial characterization. J. Clin. Endocrinol. Metab., 62, 134–141.

    Article  PubMed  CAS  Google Scholar 

  45. Baumann G., Shaw M.A. (1990): A second lower affinity growth hormone binding protein in human plasma. J. Clin. Endocrinol. Metab., 70, 680–686.

    Article  PubMed  CAS  Google Scholar 

  46. Baumann G., Amburn K., Shaw M.A. (1988): The circulating growth hormone (GH)-binding protein complex: A major constituent of plasma GH in man. Endocrinology, 122, 976–984.

    Article  PubMed  CAS  Google Scholar 

  47. Baumann G., Shaw M.A., Amburn K. (1989): Regulation of plasma growth hormone-binding proteins in health and disease. Metabolism, 38, 683–689.

    Article  PubMed  CAS  Google Scholar 

  48. Baumann G., Amburn K., Buchanan T.A. (1987): The effect of circulating growth hormone-binding protein on metabolic clearance, distribution, and degradation of human growth hormone. J. Clin. Endocrinol. Metab., 64, 657–660.

    Article  PubMed  CAS  Google Scholar 

  49. Baumann G., Shaw M.A., Buchanan T.A. (1988): In vivo kinetics of a covalent growth hormone-binding protein complex. Metabolism, 38, 330–333.

    Article  Google Scholar 

  50. Leung D.W., Spencer S.A., Cachianes G. (1987): Growth hormone receptor and serum binding protein: purification cloning and expression. Nature, 330, 537–543.

    Article  PubMed  CAS  Google Scholar 

  51. Amit T., Barkey R.J., Youdim M.B.H., Hochberg Z. (1990): A new and convenient assay for growth hormone-binding protein activity in human serum. J. Clin. Endocrinol. Metab., 71, 474–479.

    Article  PubMed  CAS  Google Scholar 

  52. Laron Z., Klinger B., Erster B., Silbergeld. (1989): Serum GH binding protein activities identifies the heterozygous carriers for Laron type dwarfism. Acta Endocrinol., 121, 603–608.

    PubMed  CAS  Google Scholar 

  53. Baumann G., Shaw M.A., Merimee T.J. (1989): Low levels of high-affinity growth hormone-binding protein in African pygmies. N. Engl. J. Med., 320, 1705–1709.

    Article  PubMed  CAS  Google Scholar 

  54. Rutanen E.M., Pekonen F. (1990): Insulin-like growth factors and their binding proteins. Acta Endocrinol., 123, 7–13.

    PubMed  CAS  Google Scholar 

  55. Zapf J., Hauri C., Waldvogel M., et al. (1989): Recombinant insulin-like growth factor-I induces its own specific carrier protein in hypophysectomized and diabetic rats. Proc. Natl. Acad. Sci. USA, 86, 3813–3817.

    Article  PubMed  CAS  Google Scholar 

  56. Binoux M., Lalou C., Lassarre C., Segovia B.. (1994): Regulation of IGF bioavailability by IGFBP proteases. In: Baxter R.C., Gluckman P.D., Rosenfeld R.G. (Eds.): The Insulin-like Growth Factors and their Regulatory Proteins. Amsterdam, Elsevier, pp. 217–226.

    Google Scholar 

  57. Havredaki M., Barona F. (1985): Variations in interferon inactivators and/or inhibitors in human serum and their relationship to interferon therapy. Jpn. J. Med. Sci. Biol., 38, 107–111.

    PubMed  CAS  Google Scholar 

  58. Fernandez-Botran R., Vitetta E.S. (1990): A soluble, high-affinity, interleukin-4-binding protein is present in the biological fluids of mice. Proc. Natl. Acad. Sci. USA, 87, 4202–4206.

    Article  PubMed  CAS  Google Scholar 

  59. Lelchuk R., Playfair J.H.L. (1985): Serum IL-2 inhibitor in mice. I. Increase during infection. Immunology, 56, 113–118.

    PubMed  CAS  Google Scholar 

  60. Malik S., Lantz M. Slevin M., Olsson I.. (1991): Infusion of recombinant human tumour necrosis factor (rhTNF) causes an increase in circulating TNF-binding protein in man. Int. J. Exp. Pathol., 72, A6.

    Google Scholar 

  61. Kleinbloesem C.H., van Brummelen P., van de Linde J.A., Voogol P.J., Breimer D.D. (1984): Nifedipine: kinetics and dynamics in healthy subjects. Clin. Pharm. Ther., 35, 742–749.

    CAS  Google Scholar 

  62. Van Cauter E., Refetoff S. (1985): Multifactorial control of the 24-hour secretory profiles of pituitary hormones. J. Endocrinol. Invest., 8, 381–391.

    PubMed  Google Scholar 

  63. Hulse J.A., Rosenthal S.M., Cuttler L., Kaplan S.L., Grumbach M.M. (1986): The effect of pulsatile administration, continuous infusion and diurnal variation on the growth hormone response to GH-releasing hormone in normal men. J. Clin. Endocrinol. Metab., 63, 872–878.

    Article  PubMed  CAS  Google Scholar 

  64. Clark R.G., Jansson J-O., Isaksson O., Robinson I.C.A.F. (1985): Intravenous growth hormone: growth responses to patterned infusions in hypophysectomized rats. J. Endocrinol., 104, 53–61.

    Article  PubMed  CAS  Google Scholar 

  65. Tuvemo T. (1989): What is the best mode of growth hormone administration? Acta Paediatr. Scand., 362 Suppl., 44–49.

    Article  CAS  Google Scholar 

  66. Tam C.S., Heersche J.N.M., Murray T.M., Parsons J.A. (1982): Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. Endocrinology, 110, 506–512.

    Article  PubMed  CAS  Google Scholar 

  67. Klabunde R.E., Burke S.E., Henkin J. (1990): Enhanced lytic efficacy of multiple bolus injections of tissue plasminogen activator in dogs. Thromb. Res., 58, 511–517.

    Article  PubMed  CAS  Google Scholar 

  68. Vickery B.H. (1991): Biological actions of synthetic analogues of luteinizing hormone-releasing hormone. In: Garzone P.D., Colburn W.A., Mokotoff M. (Eds) Pharmacokinetics and Pharmacodynamics. Vol. 3. Peptides, Peptoids and Proteins. Cincinnati, Harvey Whitney Books, pp. 41–49.

    Google Scholar 

  69. Wills R.J., Dennis S., Spiegel H.E., Gibson D.M., Nadler P.I. (1984): Interferon kinetics and adverse reactions after intravenous, intramuscular and subcutaneous injection. Clin. Pharm. Ther., 35, 722–727.

    CAS  Google Scholar 

  70. Supersaxo A., Hein W., Gallati H., Steffen H. (1988): Recombinant human interferon alpha-2a: delivery to lymphoid tissue by selected modes of application. Pharm. Res., 5, 472–476.

    Article  PubMed  CAS  Google Scholar 

  71. Supersaxo A., Hein W.R., Steffen H. (1990): Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm. Res., 7, 167–169.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Affiliations

  1. Medeval Ltd, University of Manchester, Skelton House, Manchester Science Park, Lloyd Street North, M15 6SH, Manchester, UK

    S. Toon PhD

Authors
  1. S. Toon PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Toon, S. The relevance of pharmacokinetics in the development of biotechnology products. European Journal of Drug Metabolism and Pharmacokinetics 21, 93–103 (1996). https://doi.org/10.1007/BF03190257

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03190257

Keywords

  • Biotechnology
  • pharmacokinetics
  • bioanalysis
  • binding proteins
  • drug development